Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
The dynamics of improving patient care take center stage during RhED Talks, a set of vibrant and compelling TED-style presentations focused on helping rheumatologists stay in sync with the latest developments in rheumatoid arthritis (RA). Fast-paced and succinctly delivered, each RhED Talk features a unique speaker and topic. Talks explore the newest developments in the field, provide insight into measures for assessing treat-to-target outcomes, and pinpoint treatment issues related to risk of postoperative infection and comorbidities that have a direct impact on clinical practice and patients. A question-and-answer session at the end of the presentation features a lively exchange of knowledge and ideas.
The target audience for this activity is rheumatologists. Other healthcare professionals, including physician assistants and nurse practitioners who treat patients with RA, may also benefit from participation.
Upon completion of this activity, participants should be able to:
Discuss the challenges and benefits of using ACR-recommended RA disease activity measures
Describe emerging measures for assessing treat-to-target outcomes
Summarize data on the risk of postoperative infection in patients with RA
Recall the impact of conventional and biologic disease-modifying antirheumatic drug therapy on risk of postoperative infection
Identify common comorbidities in patients with RA
Choose initial therapy for patients with significant renal, hepatic, and pulmonary disorders
Conflict Of Interest Disclosure Policy
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s).* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Alvin F. Wells, MD, PhD Visiting Professor, Karolinska Institute, Stockholm, Sweden Director, Rheumatology and Immunotherapy Center, Franklin, Wisconsin Adjunct Assistant Professor, Duke University Medical Center, Durham, North Carolina Clinical Assistant Professor, Marquette University, Milwaukee, Wisconsin
Karen Hansen, MD, MS Activity Chairperson Associate Professor, Department of Rheumatology and Endocrinology University of Wisconsin-Madison Madison, Wisconsin
Sheetal Desai, MD, MSEd Program Director, Rheumatology Associate Clinical Professor of Medicine, Division of Rheumatology University of California, Irvine Irvine, California
Faculty Disclosures: The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
Faculty: Sheetal Desai, MD, MSEd; Karen Hansen, MD, MS Independent Reviewer: Maria Dall’Era, MD
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Faculty: Alvin F. Wells, MD, PhD, has disclosed that he is on the Speakers Bureau for AbbVie, Amgen, Bristol-Myers Squibb, and Janssen
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
Planners (Forefront Collaborative): Miranda Armie; Mark Luckie; Marianna Shershneva, MD, PhD
AMA PRA Category 1 Credit(s)TM
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Forefront Collaborative designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This continuing medical education activity will not include reference(s) to unlabeled or unapproved uses of drugs or devices.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative or commercial supporter.
There are no fees or prerequisites for participating in and receiving credit for this online educational activity. In order to obtain credit for participating in this activity during the period of January 2016 through September 2016, participants must: 1. Read the educational objectives and disclosure statements. 2. Complete the online enduring material, which consists of a video and question-and-answer session. 3. Complete the post-test (must receive a minimum score of 70%) and evaluation.
You will receive your certificate after completion of the post-test and evaluation. This activity should take 1.25 hours to complete.